Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).

NCT05116189 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

643

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer
Carcinoma, Ovarian Epithelial
Fallopian Tube Neoplasms

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Paclitaxel
DRUG: Bevacizumab
OTHER: Placebo for pembrolizumab
DRUG: Docetaxel

Sponsor

Merck Sharp & Dohme LLC